Effect of sublingual application of cannabinoids on intraocular pressure

A pilot study

Ileana Tomida, Augusto Azuara-Blanco, Heather House, Maggie Flint, Roger Guy Pertwee, Philip J. Robson

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetra-hydrocannabinol (Delta-9-THC) and cannabidiol (CBD).
Patients and Methods: A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Delta-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM Of 5mg Delta-9-THC, 20mg CBD, 40mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects.
Results: Two hours after sublingual administration of 5mg Delta-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P = 0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P = 0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Delta-9-THC administration.
Conclusions: A single 5 mg sublingual dose of Delta-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40mg CBD produced a transient increase IOP rise.

Original languageEnglish
Pages (from-to)349-353
Number of pages5
JournalJournal of Glaucoma
Volume15
Issue number5
DOIs
Publication statusPublished - Oct 2006

Keywords

  • delta-9-tetrahydrocannabinol
  • cannabidiol
  • glaucoma
  • IOP
  • ocular toxicity
  • messenger RNA
  • receptor CB1
  • Delta-9-tetrahydrocannabinol
  • neurotoxicity
  • involvement
  • injury
  • eye

Cite this

Effect of sublingual application of cannabinoids on intraocular pressure : A pilot study. / Tomida, Ileana; Azuara-Blanco, Augusto; House, Heather; Flint, Maggie; Pertwee, Roger Guy; Robson, Philip J.

In: Journal of Glaucoma, Vol. 15, No. 5, 10.2006, p. 349-353.

Research output: Contribution to journalArticle

Tomida, Ileana ; Azuara-Blanco, Augusto ; House, Heather ; Flint, Maggie ; Pertwee, Roger Guy ; Robson, Philip J. / Effect of sublingual application of cannabinoids on intraocular pressure : A pilot study. In: Journal of Glaucoma. 2006 ; Vol. 15, No. 5. pp. 349-353.
@article{d30e7b1dba5b46d385cf7cd49d9b507a,
title = "Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study",
abstract = "Purpose: The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetra-hydrocannabinol (Delta-9-THC) and cannabidiol (CBD). Patients and Methods: A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Delta-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM Of 5mg Delta-9-THC, 20mg CBD, 40mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects. Results: Two hours after sublingual administration of 5mg Delta-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P = 0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P = 0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Delta-9-THC administration. Conclusions: A single 5 mg sublingual dose of Delta-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40mg CBD produced a transient increase IOP rise.",
keywords = "delta-9-tetrahydrocannabinol, cannabidiol, glaucoma, IOP, ocular toxicity, messenger RNA, receptor CB1, Delta-9-tetrahydrocannabinol, neurotoxicity, involvement, injury, eye",
author = "Ileana Tomida and Augusto Azuara-Blanco and Heather House and Maggie Flint and Pertwee, {Roger Guy} and Robson, {Philip J.}",
year = "2006",
month = "10",
doi = "10.1097/01.ijg.0000212260.04488.60",
language = "English",
volume = "15",
pages = "349--353",
journal = "Journal of Glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Effect of sublingual application of cannabinoids on intraocular pressure

T2 - A pilot study

AU - Tomida, Ileana

AU - Azuara-Blanco, Augusto

AU - House, Heather

AU - Flint, Maggie

AU - Pertwee, Roger Guy

AU - Robson, Philip J.

PY - 2006/10

Y1 - 2006/10

N2 - Purpose: The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetra-hydrocannabinol (Delta-9-THC) and cannabidiol (CBD). Patients and Methods: A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Delta-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM Of 5mg Delta-9-THC, 20mg CBD, 40mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects. Results: Two hours after sublingual administration of 5mg Delta-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P = 0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P = 0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Delta-9-THC administration. Conclusions: A single 5 mg sublingual dose of Delta-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40mg CBD produced a transient increase IOP rise.

AB - Purpose: The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetra-hydrocannabinol (Delta-9-THC) and cannabidiol (CBD). Patients and Methods: A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Delta-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM Of 5mg Delta-9-THC, 20mg CBD, 40mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects. Results: Two hours after sublingual administration of 5mg Delta-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P = 0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P = 0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Delta-9-THC administration. Conclusions: A single 5 mg sublingual dose of Delta-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40mg CBD produced a transient increase IOP rise.

KW - delta-9-tetrahydrocannabinol

KW - cannabidiol

KW - glaucoma

KW - IOP

KW - ocular toxicity

KW - messenger RNA

KW - receptor CB1

KW - Delta-9-tetrahydrocannabinol

KW - neurotoxicity

KW - involvement

KW - injury

KW - eye

U2 - 10.1097/01.ijg.0000212260.04488.60

DO - 10.1097/01.ijg.0000212260.04488.60

M3 - Article

VL - 15

SP - 349

EP - 353

JO - Journal of Glaucoma

JF - Journal of Glaucoma

SN - 1057-0829

IS - 5

ER -